LONG-LIFE Study
An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life (The LONG-LIFE Study)
Main Investigator: Charles Raison, MD
Vail Health Behavioral Health is conducting this investigational study to explore whether psilocybin may affect certain changes in the body related to aging.
Psilocybin is a drug with temporary psychedelic effects that is not approved by the US Food and Drug Administration (FDA). The use of psilocybin in this research study is experimental.
Please note, this study is for research purposes only and not intended as a treatment. Additional study details are provided below.
Study Description
| Population | Older adults (ages 60-80) |
| Overall Status | Recruiting |
What’s Involved
If you participate, this study involves up to 17 different study visits over the course of one year. If you are found to be eligible for the study, you will be assigned to one of four treatment groups:
- One dose of psilocybin with therapeutic support
- Two doses of psilocybin with therapeutic support (roughly one month apart)
- Three doses of psilocybin with therapeutic support (roughly one month apart)
- Waitlist Control: You will not receive psilocybin during your 1-year participation in the study, but will be offered a single dose of psilocybin with therapeutic support after you complete your final study visit.
Regardless of group assignment, all study participants will complete:
- A screening visit (4 hours) to check if you’re eligible to participate in the study. You’ll complete screening assessments including height, weight, a heart rhythm test, and a physical exam. You will also complete questionnaires and give blood and urine samples. If eligible and taking medications that may interfere with study participation, you may be asked to slowly come off these medications under the close supervision of the study team.
- A baseline visit (up to 2 hours) where you’ll complete assessments and provide a blood sample and fecal sample. At this visit, you will be assigned to one of four treatment groups, which will determine how many doses of psilocybin you receive.
- Six follow up assessment visits (1-2 hours each) where you will be asked to complete assessments and provide biological samples.
If you are in one of the three psilocybin treatment groups, you will be asked to complete additional visits, including:
- Preparation sessions (2 hours each) toprepare for your psilocybin dosing sessions with trained facilitators. The number of prep sessions corresponds to the number of dosing sessions you complete.
- Psilocybin dosing sessions (8-10 hours each) during which you’ll take 25 mg of psilocybin under supervision.
- Integration Sessions (1 hour each) where you’ll meet with your facilitators to integrate your dosing experience(s). “Integrate” means you will discuss and reflect on your experiences with trained facilitators to help you understand and process the effects of the psilocybin treatment. The number of integration sessions corresponds to the number of dosing sessions you complete.
During the study, you’ll also use a special app (the Fabla app) to fill out questionnaires and record voice diaries at home for three separate one-week periods during the study.
Participant Information
Who Can Participate
| Participants Must |
|---|
| 1. Be 60 to 80 years old. |
| 2. Speak English (able to provide informed consent and complete questionnaires in English). |
| 3. Be willing to comply with all study procedures and available for the duration of the study. |
| 4. Be able to swallow capsules. |
| 5. Be medically healthy. |
Financial Compensation
Participants will be compensated for their time and participation. The total compensation may be up to $2,470, depending on the number of study visits and assessments completed.
Will volunteering for this study help me?
Receiving psilocybin with psychological support in a clinical trial may improve your well-being. It is also possible that psilocybin will not have a positive impact and might have unpleasant side effects. Even if the study doesn’t directly benefit you, your participation could help others in the future by advancing our understanding of how psilocybin impacts aging.
How To Participate
If you’re interested in joining our research study, please complete the pre-screening form by clicking the “See if You Pre-Qualify” button. This will help us determine if you meet the initial qualifications for participation.
Should you qualify, a member of our study team will reach out to you for a follow-up interview and further assessment.
Study Locations

Wiegers Clinic
Primary Location
439 Edwards Access Road
Ste. B204
Edwards, CO 81632

Buck Creek Medical Plaza
Secondary Location
50 Buck Creek Road
Ste. 015
Avon, CO 81620
Questions?
Contact our team
For additional questions, please contact the LONG-LIFE study team at BHIC@vailhealth.org or (970) 855-7374.
